Added to YB: 2025-02-03
Pitch date: 2025-02-01
TEVA [bullish]
Teva Pharmaceutical Industries Limited
+68.97%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Market Cap
$30.7B
Pitch Price
$17.63
Price Target
27.00 (-9%)
Dividend
N/A
EV/EBITDA
9.65
P/E
43.30
EV/Sales
2.72
Sector
Pharmaceuticals
Category
growth
$TEVA: A Strong Case for Recovery Despite Earnings-Driven Overreaction
TEVA: Q4 miss overblown. Strong fundamentals intact. AUSTEDO +34% YoY, UZEDY +419%. Generics +11%. 7 biosimilars 2025-27. Debt reduced $18.4B to $14.7B. Margin expansion via manufacturing optimization. 45% upside potential. 7.6x P/E, 9% EPS CAGR through 2027. Long-term growth story unfolding.
Read full article (4 min)